These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32958298)

  • 1. Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, et al. Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Eur Urol 2020;78:540-3.
    Hopkins AM; Kichenadasse G; Sorich MJ
    Eur Urol; 2020 Dec; 78(6):e227. PubMed ID: 32958298
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, et al. Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Eur Urol 2020;78:540-3.
    Funada S; Yoshioka T; Luo Y
    Eur Urol; 2020 Dec; 78(6):e225-e226. PubMed ID: 32958297
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Cosimo De Nunzio, Benjamin Brucker, Thomas Bschleipfer, et al. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. Eur Urol 2021;79:492-504.
    De Nunzio C; Brucker B; Bschleipfer T; Cornu JN; Drake MJ; Fusco F; Gravas S; Oelke M; Peyronnet B; Tutolo M; van Koeveringe G; Madersbacher S
    Eur Urol; 2021 May; 79(5):e147-e148. PubMed ID: 33685837
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
    Moris L; Van den Broeck T; Wiegel T;
    Eur Urol; 2020 Sep; 78(3):e120-e121. PubMed ID: 32684306
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, et al. Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Clin Cancer Res. In press. https://doi.org/10.1158/1078-0432.CCR-20-1876.
    Funada S; Yoshioka T; Luo Y
    Eur Urol Oncol; 2020 Oct; ():. PubMed ID: 34756420
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Marcus J. Drake, Amanda L. Lewis, Grace J. Young, et al. Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals. Eur Urol 2020;78:701-10.
    Young G; Blair P; Lewis A; Drake MJ; Athene Lane J
    Eur Urol; 2021 Mar; 79(3):e89-e90. PubMed ID: 33357995
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Satoshi Funada, Takashi Yoshioka, and Luo Yan's Letter to the Editor re: Guohua Zeng, Chao Cai, Xianzhong Duan, et al. Mini Percutaneous Nephrolithotomy Is a Noninferior Modality to Standard Percutaneous Nephrolithotomy for the Management of 20-40mm Renal Calculi: A Multicenter Randomized Controlled Trial. Eur Urol 2021;79:114-21.
    Cai C; Zeng G
    Eur Urol; 2021 Feb; 79(2):e62. PubMed ID: 33221090
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Francesco Massari and Vincenzo Di Nunno's Letter to the Editor re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8.
    Perez-Gracia JL
    Eur Urol; 2018 Jul; 74(1):e14. PubMed ID: 29656856
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8.
    Massari F; Di Nunno V
    Eur Urol; 2018 Jul; 74(1):e12-e13. PubMed ID: 29656855
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Yan Shibing and Wei Qiang's Letter to the Editor re: Morgan Rouprêt, Marko Babjuk, Eva Compérat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
    Rouprêt M
    Eur Urol; 2016 Mar; 69(3):e51-2. PubMed ID: 26461109
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Thomas Gevaert, Markus Eckstein, Rodolfo Montironi, and Antonio Lopez-Beltran's Letter to the Editor re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538-40.
    Rijnders M; van der Veldt AAM; de Wit R; van Leenders GJLH
    Eur Urol; 2019 Jun; 75(6):e160-e161. PubMed ID: 30723047
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-61.
    Babjuk M; Burger M; Compérat E; Palou J; Rouprêt M; van Rhijn B; Shariat S; Sylvester R; Zigeuner R; Gontero P; Mostafid H
    Eur Urol; 2017 Jun; 71(6):e173-e174. PubMed ID: 27939074
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.
    Vila-Reyes H; Joel DeCastro G; McKiernan JM
    Eur Urol; 2021 Feb; 79(2):e54-e55. PubMed ID: 33248798
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Yuxuan Song, Caipeng Qin, and Tao Xu's Letter to the Editor re: J. Alberto Nakauma-González, Maud Rijnders, Job van Riet, et al. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. Eur Urol 2022;81:331-6.
    Nakauma-González JA; Rijnders M; van de Werken HJG; Lolkema MPJ; Boormans JL
    Eur Urol; 2022 Sep; 82(3):e78-e79. PubMed ID: 35717359
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to Stephen B. Williams and Ashish M. Kamat's Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol 2016;69:60-9.
    Sylvester R; Gontero P; Oddens J
    Eur Urol; 2016 Jun; 69(6):e123-4. PubMed ID: 26874805
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.
    Panebianco V; Del Giudice F; Narumi Y; Simone G; De Berardinis E; Catto JWF
    Eur Urol; 2021 Feb; 79(2):e52-e53. PubMed ID: 33261940
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al's Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269-76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation.
    van Dijk N; Gómez de Liaño Lista A; Szabados B; Powles T; van der Heijden MS
    Eur Urol; 2021 Jan; 79(1):e20-e21. PubMed ID: 33153815
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
    Fukuokaya W; Egawa S
    Eur Urol; 2021 Apr; 79(4):553-554. PubMed ID: 33277082
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Hao Lun Luo, Yen Ta Chen, Yuan Tso Cheng, and Po Hui Chiang's Letter to the Editor re: Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. Eur Urol 2016;70:1052-68: The Key Role of Flexible Ureterorenoscopy in Kidney-sparing Surgery for Upper Tract Urothelial Carcinoma.
    Seisen T; Babjuk M; Rouprêt M
    Eur Urol; 2017 Apr; 71(4):e111-e112. PubMed ID: 27666997
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to M.V. Meng's Letter to the Editor re: H. Baumert et al. The use of polymer (Hem-o-lok) clips for management of the renal hilum during laparoscopic nephrectomy. Eur Urol 2006;49:816-9 and P.L. Steinberg et al. re: H. Baumert et al. The use of polymer (Hem-o-lok) clips for management of the renal hilum during laparoscopic nephrectomy. Eur Urol 2006;49:816-9. Eur Urol 2007;51:572-3.
    O'Kane HF; Nambirajan T
    Eur Urol; 2007 May; 51(5):1449. PubMed ID: 17229516
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.